Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 1
Submit an article Journal homepage
203
Views
60
CrossRef citations to date
0
Altmetric
Review

Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA

Ram I Mahato University of Tennessee Health Science Center, Department of Pharmaceutical Sciences, 26 South Dunlap Street, Feurt Bldg RM 406, Memphis, TN 38163, USA. [email protected]
,
Kun Cheng University of Tennessee Health Science Center, Department of Pharmaceutical Sciences, 26 South Dunlap Street, Feurt Bldg RM 406, Memphis, TN 38163, USA. [email protected]
&
Ramareddy V Guntaka University of Tennessee Health Science Center, Department of Pharmaceutical Sciences, 26 South Dunlap Street, Feurt Bldg RM 406, Memphis, TN 38163, USA. [email protected]
Pages 3-28 | Published online: 22 Apr 2005

Bibliography

  • CROOKE ST: Progress in antisense technology. Ann. Rev Med. (2004) 55:61–95.
  • ••Comprehensive review on backbonemodification, cellular uptake and biodistribution of ODNs.
  • OPALINSKA JB, GEWIRTZ AM: Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. (2002) 1(7):503–514.
  • ••Excellent review on different types ofnucleic acids used for blocking abnormal gene expression.
  • SONG E, LEE SK, WANG J et al: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. (2003) 9(3):347–351.
  • •An important study demonstrating the therapeutic usefulness of siRNA in hepatitis mouse model.
  • GUNTAKA RV VARMA BR, WEBER KT: Triplex-forming oligonucleotides as modulators of gene expression. Int. J. Biochem. Cell Biol. (2003) 35(1):22–31.
  • SEIDMAN MM, GLAZER PM: The potential for gene repair via triple helix formation. J. Clin. Invest. (2003) 112(4):487–494.
  • VASQUEZ KM, GLAZER PM: Triplex-forming oligonucleotides: principles and applications. Q. Rev. Biophys. (2002) 35(1):89–107.
  • CROOKE ST, BENNETT CF: Progress in antisense oligonucleotide therapeutics. Ann. Rev. Pharmacol Toxicol (1996) 36:107–129.
  • ZAMECNIK PC, STEPHENSON ML: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA (1978) 75(1):280–284.
  • CROOKE ST: Vitravene-another piece in the mosaic. Antisense Nucleic Acid DrugDev. (1998) 8(4):vii-viii.
  • LEE M, HAN SO, KO KS et al.: Repression of GAD autoantigen expression in pancreas beta-Cells by delivery of antisense plasmid/PEG-y-PLL complex. Mo/. Ther. (2001) 4(4):339–346.
  • LONG MB, JONES JP, 3rd, SULLENGER BA et al.: Ribozyme-mediated revision of RNA and DNA. J. Clin. Invest. (2003) 112(3):312–318.
  • BUCHARDT O, EGHOLM M, BERG RH et al.: Peptide nucleic acids and their potential applications in biotechnology Trends Biotechnol (1993) 11(9):384–386.
  • WALL NR, SHI Y: Can RNA interference be exploited for therapy? Lancet (2003) 362(9393):1401–1403.
  • MAHATO RI, TAKAKURAY, HASHIDA M: Development of targeted delivery systems for nucleic acid drugs./ Drug Target. (1997) 4(6):337–357.
  • •Detailed information on how physicochemical characteristics influence the biodistribution profiles of ODNs and genes.
  • WICKSTROM E: Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods (1986) 13(2):97–102.
  • MICKLEFIELD J: Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr. Med. Chem. (2001) 8(10):1157–1179.
  • ••Excellent review on how backbonemodification of ODNs can enhance their stability and efficacy
  • KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. j Biochem. (2003) 270(8):1628–1644.
  • •Comprehensive review on the chemical modification of antisense agents.
  • AKHTAR S, JULIANO RL: Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. (1992) 2(5):139–144.
  • HU Q, BALLY MB, MADDEN TD: Subcellular trafficking of antisense oligonucleotides and down regulation of bc1-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res. (2002) 30(161:3632–3641.
  • BULMUS V, WOODWARD M, LIN L et al.: A new pH-responsive and glutathione-reactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs. J. Control. Release (2003) 93(2):105–120.
  • ALAHARI SK, DEAN NM, FISHER MH et al.: Inhibition of expression of the multi-drug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol (1996) 50(4):808–819.
  • JENSEN KD, KOPECKOVA P, KOPECEK J: Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. Bioconjug Chem. (2002) 13(5):975–984.
  • NORI A, JENSEN KD, TIJERINA M et al.: Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug Chem. (2003) 14(1):44–50.
  • MOULTON HM, HASE MC, SMITH KM et al.: HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. (2003) 13(1):31–43.
  • DAGLE JM, WEEKS DL: Oligonucleotide-based strategies to reduce gene expression. Differentiation (2001) 69(2-3):75–82.
  • FURDON PJ, DOMINSKI Z, KOLE R: RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. (1989) 17(22):9193–9204.
  • DASH P, LOTAN I, KNAPP M et al.: Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl Acad. Sci. USA (1987) 84(22):7896–7900.
  • WALDER RY, WALDER JA: Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl Acad. Sci. USA (1988) 85(14):5011–5015.
  • DAGLE JM, WEEKS DL, WALDER JA: Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res. Dev. (1991) 1(1):11–20.
  • MONIA BP, LESNIK EA, GONZALEZ C et al.: Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. (1993) 268(19):14514–14522.
  • HEASMAN J: Morpholino oligos: making sense of antisense? Dev. Biol. (2002) 243(2): 209–214.
  • Fomivirsen approved for CMV retinitis: first antisense drug. AIDS Treat. News (1998) 302:7.
  • ECKSTEIN F: Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. (2000) 10(2):117–121.
  • CAMPBELL JM, BACON TA, WICKSTROM E: Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods (1990) 20(3):259–267.
  • THIERRY AR, VIVES E, RICHARD JP et al.: Cellular uptake and intracellular fate of antisense oligonucleotides. Curr. Opin. Mol Ther. (2003) 5(2):133–138.
  • CROOKE ST: Progress in antisense technology: the end of the beginning. Methods Enqmol. (2000) 313:3–45.
  • TONKINSON JL, STEIN CA: Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer Invest. (1996) 14(1):54–65.
  • KRIEG AM, STEIN CA: Phosphorothioate oligodeoxynucleotides: antisense or antiprotein? Antisense Res. Dev. (1995) 5(4):241.
  • GALBRAITH WM, HOBSON WC, GICLAS PC et al.: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. (1994) 4 (3): 201–206.
  • SARMIENTO UM, PEREZ JR, BECKER JM et al.: In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. (1994) 4(2):99–107.
  • AGRAWAL S, KANDIMALLA ER: Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today (2000) 6(2):72–81.
  • ZAMARATSKI E, PRADEEPKUMAR PI, CHATTOPADHYAYA J: A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J. Biochem. Biophys. Methods (2001) 48(3):189–208.
  • BAKER BF, LOT SS, CONDON TP et al.: 2'-0-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem. (1997) 272(18):11994–12000.
  • RUSCKOWSKI M, QU T, ROSKEY A et al.: Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice. Antisense Nucleic Acid Drug Dev. (2000) 10(5):333–345.
  • AGRAWAL S, JIANG Z, ZHAO Q et al: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. NatL Acad. Sci. USA (1997) 94(6):2620–2625.
  • VERMA S, ECKSTEIN F: Modified oligonucleotides: synthesis and strategy for users. Ann. Rev. Biochem. (1998) 67: 99–134.
  • ENGELS JW, UHLMANN E: Chemistry of oligonucleotides; in Couvreur P, Malvy C (eds):PharmaceuticalAspects of Oligonucleotides. London, Taylor & Francis, (2000), pp 35–68.
  • HEIDENREICH O, GRYAZNOV S, NERENBERG M: RNase H-independent antisense activity of oligonucleotide N3 > P5 phosphoramidates. Nucleic Acids Res. (1997) 25(4):776–780.
  • SKORSKI T, PERROTTI D, NIEBOROWSKA-SKORSKA M et al: Antileukaemia effect of c-myc N3'- > P5' phosphoramidate antisense oligonucleotides in vivo. Proc Nati Acad Sci USA (1997) 94(8):3966–3971.
  • GRYAZNOV SM, LLOYD DH, CHEN JK et al.: Oligonucleotide N3'- > P5' phosphoramidates. Proc. Nati Acad. Sci. USA (1995) 92(13):5798–5802.
  • SUMMERTON J, WELLER D: Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. (1997) 7(3):187–195.
  • SUMMERTON J: Morpholino antisenseoligomers: the case for an RNase independent structural type. Biochim. Biophys. Acta. (1999) 1489(1):141–158. Excellent review on morpholino antisense ODNs.
  • HUDZIAK RM, BAROFSKY E, BAROFSKY DF et al.: Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. (1996) 6(4):267–272.
  • DOMINSKI Z, KOLE R: Restoration of correct splicing in thalassemic premRNA by antisense oligonucleotides. Proc. NatL Acad. Sci. USA (1993) 90(18):8673–8677.
  • SUWANMANEE T, SIERAKOWSKA H, LACERRA G et al: Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. MoL PharmacoL (2002) 62(3):545–553.
  • HEASMAN J: Morpholino oligos: making sense of antisense? Dev. Biol. (2002) 243(2):209–214.
  • SUMMERTON J, STEIN D, HUANG SB et al.: Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. (1997) 7(2):63–70.
  • TAYLOR MF, PAULAUSKIS JD, WELLER DD et al.: In vitro efficacy of morpholino-modified antisense oligomers directed against tumour necrosis factor-alpha mRNA. J. Biol. Chem. (1996) 271(29):17445–17452.
  • GILES RV SPILLER DG, CLARK RE et al.: Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev. (1999) 9(2):213–220.
  • STEIN DA, SKILLING DE, IVERSEN PL et al: Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid DrugDev. (2001) 11(5):317–325.
  • ARORA V, IVERSEN PL: Redirection of drug metabolism using antisense technology. Curr. Opin. MoL Ther. (2001) 3(3):249–257.
  • ARORA V, GATE ML, GHOSH C et al.: Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab. Dispos. (2002) 30(7):757–762.
  • VIKRAM A, DEREK CK, MURALIMOHAN TR, DWIGHT DW, PATRICK LI: Bioavailability and Efficiency of Antisense Morpholino Oligomers Targeted to c-myc and Cytochrome P450 3A2 Following Oral Administration in Rats. J.Pharm. Sci. (2002) 91(4):1009–1018.
  • MCCAFFREY AP, MEUSE L, KARIMI M et al.: A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepato/ogy (2003) 38(2):503–508.
  • IVERSEN PL, ARORA V, ACKER AJ et al.: Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. (2003) 9(7):2510–2519.
  • SCHMAJUK G, SIERAKOWSKA H, KOLE R: Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J. Biol. Chem. (1999) 274(31):21783–21789.
  • SAZANI P, KANG SH, MATER MA et al.: Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. (2001) 29(19):3965–3974.
  • SAZANI P, GEMIGNANI F, KANG SH et al.: Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol (2002) 20(12):1228–1233.
  • KRIEG AM: Immune effects and mechanisms of action of CpG motifs. Vaccine (2000) 19(0:618–622.
  • SCHEULE RK: The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev (2000) 44(2–3):119-134. Excellent review on CpG motifs.
  • KRIEG AM, YT AK, MATSON S et al.: CpG motifs in bacterial DNA trigger direct B cell activation. Nature (1995) 374(6522):546–549.
  • PAYETTE PJ, DAVIS HL, KRIEG AM: Role of CpG motifs in immunostimulation and gene expression; in Mahato RIaK, S.W. (ed):Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics. London, Taylor & Francis, (2002), pp 467–486. Excellent review on CpG motifs.
  • KANDIMALLA ER, BHAGAT L, ZHU FG et al: A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and over-rides species-specific recognition observed with CpG motif. Proc Natl. Acad. Sci. USA (2003) 100(2014303–14308.
  • DOVE A: Antisense and sensibility. Nat. BiotechnoL (2002) 20(2):121–124.
  • LONSDORF AS, KUEKREK H, STERN BV et al: Intratumour CpG-oligodeoxynucleotide injection induces protective antitumour T cell immunity. J. Immunol (2003) 171(8):3941–3946.
  • DALPKE A, ZIMMERMANN S, HEEG K: Immunopharmacology of CpG DNA. Biol. Chem. (2002) 383(10):1491–1500.
  • AGRAWAL S, KANDIMALLA ER: Medicinal chemistry and therapeutic potential of CpG DNA. Trends MoL Med. (2002) 8(3):114–121.
  • KANDIMALLA ER, BHAGAT L, YU D et al.: Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. Bioconjug. Chem. (2002) 13(5):966–974.
  • YU D, ZHU FG, BHAGAT L et al.: PotentCpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem. Biophys. Res. Commun. (2002) 297(1):83–90.
  • PRASEUTH D, GUIEYSSE AL, HELENE C: Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim. Biophys. Acta (1999) 1489(1):181–206.
  • MAHER LJ 3rd: Prospects for the therapeutic use of antigene oligonucleotides. Cancer Invest. (1996) 14(1):66–82.
  • POTAMAN VN: Applications of triple-stranded nucleic acid structures to DNA purification, detection and analysis. Expert Rev. MoL Diagn. (2003) 3(4):481–496.
  • GEWIRTZ AM, SOKOL DL, RATAJCZAK MZ: Nucleic acid therapeutics: state of the art and future prospects. Blood (1998) 92(3):712–736. Excellent review on nucleic acid-based therapeutics.
  • OLIVAS WM, MAHER LJ 3rd: Competitive triplex/quadruplex equilibria involving guanine-rich oligonucleotides. Biochemistry (1995) 34(1):278–284.
  • FARUQI AF, KRAWCZYK SH, MATTEUCCI MD et al: Potassium-resistant triple helix formation and improved intracellular gene targeting by oligodeoxyribonucleotides containing 7-deazaxanthine. Nucleic Acids Res. (1997) 25(3):633–640.
  • BASYE J, TRENT JO, GAO D et al: Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/ neu promoter requires the pyrimidine motif. Nucleic Acids Res. (2001) 29(23):4873–4880.
  • LACROIX L, ARIMONDO PB, TAKASUGI M et al: Pyrimidine morpholino oligonucleotides form a stable triple helix in the absence of magnesium ions. Biochem. Biophys. Res. Commun. (2000) 270(2):363–369.
  • FERDOUS A, WATANABE H, AKAIKE T et al: Poly(L-lysine)-graft-dextran copolymer: amazing effects on triplex stabilization under physiological pH and ionic conditions (in vitro). Nucleic Acids Res. (1998) 26(17):3949–3954.
  • MARUYAMA A, WATANABE H, FERDOUS A et al: Characterization of interpolyelectrolyte complexes between double-stranded DNA and polylysine comb-type copolymers having hydrophilic side chains. Bioconjug. Chem. (1998) 9(2):292–299.
  • FERDOUS A, AKAIKE T, MARUYAMA A: Mechanism of intermolecular purine-purine-pyrimidine triple helix stabilization by comb-type polylysine graft copolymer at physiologic potassium concentration. Bioconjug Chem. (2000) 11(4):520–526.
  • CARBONE GM, MCGUFFIE E, NAPOLI S et al: DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res. (2004) 32(8):2396–2410.
  • FARIA M, WOOD CD, PERROUAULT L et al.: Targeted inhibition of transcription elongation in cells mediated by triplex-forming oligonucleotides. Proc. Natl Acad. Sci. USA (2000) 97(8):3862–3867.
  • VASQUEZ KM, NARAYANAN L, GLAZER PM: Specific mutations induced by triplex-forming oligonucleotides in mice. Science (2000) 290(5491):530–533.
  • VUORIO E, DE CROMBRUGGHE B: The family of collagen genes. Ann. Rev. Biochem. (1990) 59: 837–872.
  • VAN Der Collagen family of proteins. Faseb J. (1991) 5(13):2814–2823.
  • BRENNER DA, RIPPE RA, VELOZ Analysis of the collagen alpha 1(I) promoter. Nucleic Acids Res. (1989) 17(15):6055–6064.
  • JOSEPH J, KANDALA JC, VEERAPANANE D et al.: Antiparallel polypurine phosphorothioate oligonucleotides form stable triplexes with the rat alphal (I) collagen gene promoter and inhibit transcription in cultured rat fibroblasts. Nucleic Acids Res. (1997) 25(11):2182–2188.
  • DHALLA AK, KANDALA JC, WEBER KT et al.: Identification of negative and positive regulatory elements in the rat alpha 1(I) collagen gene promoter. Int. j Biochem. Cell Biol. (1997) 29(1):143–151.
  • WEBER KT, SWAIVIYNATHAN SK, GUNTAKA RV et al.: Angiotensin II and extracellular matrix homeostasis. Int. J. Biochem. Cell Biol. (1999) 31(3–4):395-403.
  • MUSSO M, VAN DYKE MW: Polyamine effects on purine-purine-pyrimidine triple helix formation by phosphodiester and phosphorothioate oligodeoxyribonucleotides. Nucleic Acids Res. (1995) 23(12):2320–2327.
  • NAKANISHI M, WEBER KT, GUNTAKA RV: Triple helix formation with the promoter of human alphal (I) procollagen gene by an antiparallel triplex-forming oligodeoxyribonucleotide. Nucleic Acids Res. (1998) 26(22):5218–5222. Excellent research article on TFOs.
  • FIRE A, XU S, MONTGOMERY MK et al.: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806–811.
  • COUZIN J: Breakthrough of the year. Small RNAs make big splash. Science (2002) 298(5602):2296–2297.
  • PLASTERK RH: RNA silencing: the genome's immune system. Science (2002) 296(5571):1263–1265.
  • MILHAVET O, GARY DS, MATTSON MP: RNA interference in biology and medicine. Pharmacol. Rev. (2003) 55(4):629–648. Excellent review on siRNA.
  • LIEBERMAN J, SONG E, LEE SK et al: Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends MoL Med. (2003) 9(9):397–403.
  • ZENG Y, CULLEN BR: RNA interference in human cells is restricted to the cytoplasm. RNA (2002) 8(7):855–860.
  • ZAMORE PD, TUSCHL T, SHARP PA et al.: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 101(1):25–33.
  • NYKANEN A, HALEY B, ZAMORE PD: ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell (2001) 107(3):309–321.
  • HAMMOND SM, BERNSTEIN E, BEACH D et al.: An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 404(6775):293–296.
  • DYKXHOORN DM, NOVINA CD, SHARP PA: Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. (2003) 4(6):457–467.
  • ••Excellent review on siRNA.
  • SCHWARZ DS, HUTVAGNER G, DU T et al.: Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 115(2):199–208.
  • ••Excellent research work demonstratingthat the two strands of an siRNA duplex are not equally eligible for assembly into RISC.
  • SCHIFFELERS RM, WOODLE MC, SCARIA P: Pharmaceutical prospects for RNA interference. Pharm. Res. (2004) 21(1):1–7.
  • SCHERER LJ, ROSSI JJ: Approaches for the sequence-specific knockdown of mRNA. Nat. BiotechnoL (2003) 21(12):1457–1465.
  • ••This paper discusses the application ofantisense ODNs, ribozymes, DNAzymes and RNAi.
  • HOLEN T, AIVIARZGUIOUI M, WIIGER MT et al.: Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res. (2002) 30(8):1757–1766.
  • HENSCHEL A, BUCHHOLZ F, HABERMANN B: DEQOR: A web-based tool for the design and quality control of siRNAs. Nucleic Acids Res. (2004) 32(Web Server issue):W113–W120.
  • YANG D, BUCHHOLZ F, HUANG Z et al: Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA (2002) 99(15):9942–9947.
  • KAWASAKI H, SUYAMA E, IY0 M, et al: siRNAs generated by recombinant human Dicer induce specific and significant but target site-independent gene silencing in human cells. Nucleic Acids Res. (2003) 31(3):981–987.
  • AN DS, XIE Y, MAO SH et al: Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum. Gene Ther. (2003) 14(12):1207–1212.
  • XIA H, MAO Q, PAULSON HL et al: siRNA-mediated gene silencing in vitro and in vivo. Nat. BiotechnoL (2002) 20(10):1006–1010.
  • BRUMMELKAMP TR, BERNARDS R, AGAMI R: A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 296(5567):550–553.
  • SUI G, SOOHOO C, AFFAR El B, et al: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA (2002) 99(8):5515–5520.
  • KAYKAS A, MOON RT: A plasmid-based system for expressing small interfering RNA libraries in mammalian cells. BMC Cell Biol. (2004) 5(1):16.
  • ZHENG L, LIU J, BATALOV S et al: An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. NatL Acad. Sci. USA (2004) 101(1):135–140.
  • TOMAR RS, MATTA H, CHAUDHARY PM: Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene (2003) 22(30:5712–5715.
  • ZHAO LJ, PAN H, ZHU H: Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene (2003) 316: 137–141.
  • DEVROE E, SILVER PA: Retrovirus-delivered siRNA. BMC BiotechnoL (2002) 2(1):15.
  • MATTA H, HOZAYEV B, TOMAR R et al: Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol. Ther. (2003) 2(2):206–210.
  • TISCORNIA G, SINGER O, IKAWA M et al: A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. NatL Acad. Sci. USA (2003) 100(4):1844–1848.
  • ABBAS-TERKI T, BLANCO-BOSE W, DEGLON N et al: Lentiviral-mediated RNA interference. Hum. Gene Ther. (2002) 13(18):2197–2201.
  • UI-TEI K, NAITO Y, TAKAHASHI F et al: Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. (2004) 32(3):936–948.
  • NAITO Y, YAMADA T, UI-TEI K et al.: siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res. (2004) 32(Web Server issue):W124–W129.
  • YUAN B, LATEK R, HOSSBACH M et al: siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res. (2004) 32(Web Server issue):W130–W134.
  • FRIEDRICH I, SHIR A, KLEIN S et al.: RNA molecules as anticancer agents. Semin. Cancer Biol. (2004) 14(4):223–230.
  • MAHATO RI, TAKEMURA S, AKAMATSU K et al.: Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem. PharmacoL (1997) 53(0:887–895.
  • BRUMMELKAMP TR, BERNARDS R, AGAMI R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2(3):243–247.
  • KARIKO K, BHUYAN P, CAPODICI J et al.: Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signalling through toll-like receptor 3. J. Immunol. (2004) 172(10:6545–6549.
  • ELBASHIR SM, MARTINEZ J, PATKANIOWSKA A et al.: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo/ (2001) 20(23):6877–6888.
  • JACKSON AL, BARTZ SR, SCHELTER J et al.: Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. (2003) 21(6):635–637.
  • SCACHERI PC, ROZENBLATT-ROSEN O, CAPLEN NJ et al.: Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. NatL Acad. Sci. USA (2004) 101(7):1892–1897.
  • SNOVE O Jr, HOLEN T: Many commonly used siRNAs risk off-target activity. Biochem. Biophys. Res. Commun. (2004) 319(1):256–263.
  • SAWAI K, MAHATO RI, OKAY, et al: Disposition of oligonucleotides in isolated perfitsed rat kidney: involvement of scavenger receptors in their renal uptake. J. PharmacoL Exp. Ther. (1996) 279(1):284–290.
  • ••Excellent research paper on renaldisposition of ODNs.
  • YOSHIDA M, MAHATO RI, KAWABATA K et al.: Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharm. Res. (1996) 13(4):599–603.
  • TAKAKURAY, MAHATO RI, YOSHIDA M et al.: Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acid Drug Dev. (1996) 6(3):177–183.
  • TAKAKURAY, MAHATO RI, HASHIDA M: Control of pharmacokinetic profiles of drug-macromolecule conjugates. Adv. Drug Del. Rev. (1996) 19:377.
  • TAKAKURA Y, HASHIDA M: Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. (1996) 13(6):820–831.
  • INAGAKI M, TOGAWA K, CARR BI et al.: Antisense oligonucleotides: inhibition of liver cell proliferation and in vivo disposition. Transplant. Proc. (1992) 24(6):2971–2972.
  • BIJSTERBOSCH MK, MANOHARAN M, RUMP ET et al.: In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res. (1997) 25(10:3290–3296.
  • RAPPAPORT J, HANSS B, KOPP JB et al.: Transport of phosphorothioate, et al.: Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int. (1995) 47(5):1462–1469.
  • GEARY RS, LEEDS JM, FITCHETT J et al.: Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. (1997) 25(11):1272–1281.
  • : Pharmacokinetic properties in animals; in Crooke ST (ed):Antisense Drug Technology. New York, Marcel Dekker Inc. (2001) pp 119–154.
  • DELONG RK, NOLTING A, FISHER M et al.: Comparative pharmacokinetics, tissue distribution, and tumour accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid DrugDev. (1997) 7(2):71–77.
  • YAKUBOV LA, DEEVA EA, ZARYTOVA VF et al.: Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. NatL Acad. Sci. USA (1989) 86(17):6454–6458.
  • LOKE SL, STEIN CA, ZHANG XH et al.: Characterization of oligonucleotide transport into living cells. Proc. NatL Acad. Sci. USA (1989) 86(10):3474–3478.
  • WU-PONG S, BARD J, HUFFMAN J et al.: Oligonucleotide biological activity: relationship to the cell cycle and nuclear transport. Biol. Cell (1997) 89(4):257–261.
  • SHOJI Y, AKHTAR S, PERIASAMY A et al.: Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. (1991) 19(20):5543–5550.
  • AKHTAR S, BASU S, WICKSTROM E et al.: Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res. (1991) 19(20):5551–5559.
  • STUART DD, ALLEN TM: A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta (2000) 1463(2):219–229.
  • BENNETT CF, MIREJOVSKY D, CROOKE RM et al.: Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. J. Drug Target. (1998) 5(3):149–162. ZELPHATI O, SZOKA FC Jr: Mechanism of oligonucleotide release from cationic liposomes. Proc. Nail. Acad. Sci. USA (1996) 93(21):11493–11498. Excellent research paper on mechanism of ODNs release from liposomes.
  • ZELPHATI O, SZOKA FC Jr: Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA (1996) 93(21):11493–11498.
  • •• Excellent research paper on mechanism of ODNs release from liposomes.
  • LUKACS GL, HAGGIE P, SEKSEK O, et al.: Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. (2000) 275(3):1625–1629.
  • BIESSEN EA, Vietsch H, Rump ET, et al.: Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem. J. (1999) 340 ( Pt 3):783–792.
  • GINOBBI P, GEISER TA, OMBRES D et al.: Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anti-Cancer Res. (1997) 17(1A):29–35.
  • WANG S, LEE RJ, CAUCHON G et al: Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Nail. Acad. Sci. USA (1995) 92(8):3318–3322.
  • ROJANASAKUL Y, WEISSMAN DN, SHI X et al.: Antisense inhibition of silica-induced tumour necrosis factor in alveolar macrophages. J. Biol. Chem. (1997) 272(7):3910–3914.
  • LIANG WW, SHI X, DESHPANDE D et al.: Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim. Biophys. Acta (1996) 1279(2):227–234.
  • SCHLEPPER-SCHAFER J, HULSMANN D, DJOVKAR A et al.: Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages. Exp. Cell Res. (1986) 165(2):494–506.
  • KAWABATA K, TAKAKURA Y, HASHIDA M: The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. (1995) 12(6):825–830.
  • RAJUR SB, ROTH CM, MORGAN JR et al.: Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules. Bioconjug. Chem. (1997) 8(6):935–940.
  • MATER MA, YANNOPOULOS CG, MOHAMED N et al.: Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjug. Chem. (2003) 14(1):18–29.
  • CROOKE ST, GRAHAM MJ, ZUCKERMAN JE et al.: Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. PharmacoL Exp. Ther. (1996) 277(2):923–937.
  • BIJSTERBOSCH MK, MANOHARAN M, DORLAND R et al.: bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver. J. PharmacoL Exp. Ther. (2002) 302(2):619–626.
  • MANOHARAN M: Oligonucleotide conjugates in antisense technology; in Crooke ST (ed):Antisense Drug Technology. New York, Marcel Dekker, (2001), pp 391–469. Excellent review on ODN conjugates.
  • BIJSTERBOSCH MK, MANOHARAN M, DORLAND R et al.: Delivery of cholesteryl-conjugated phosphorothioate oligodeoxynucleotides to Kupffer cells by lactosylated low-density lipoprotein. Biochem. Pharmacol. (2001) 62(5):627–633.
  • DESJARDINS J, MATA J, BROWN T et al.: Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo. J. Drug Target. (1995) 2(0:477–485.
  • EPA WR, RONG P, BARTLETT PF et al.: Enhanced down regulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. (1998) 8(6):489–498.
  • LEDOAN T, ETORE F, TENU JP et al.: Cell binding, uptake and cytosolic partition of HIV antigag phosphodiester oligonucleotides 3'-linked to cholesterol derivatives in macrophages. Bioorg Med. Chem (1999) 7(11):2263–2269.
  • GRYAZNOV SM, LLOYD DH: Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions. Nucleic Acids Res. (1993) 21(25):5909–5915.
  • LI S, DESHMUKH HM, HUANG L: Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells. Pharm. Res. (1998) 15(10):1540–1545.
  • BONORA GM, IVANOVA E, ZARYTOVA V et al.: Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides. Bioconjug Chem. (1997) 8(6):793–797.
  • HARADA-SHIBA M, YAMAUCHI K, HARADA A et al.: Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther. (2002) 9(6):407–414.
  • VINOGRADOV SV, BRONICH TK, KABANOV AV: Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug Chem. (1998) 9(6):805–812.
  • BRUS C, PETERSEN H, AIGNER A et al.: Physicochemical and biological characterization of polyethylenimine-graft-poly(ethylene glycol) block copolymers as a delivery system for oligonucleotides and ribozymes. Bioconjug Chem. (2004) 15(4):677–684.
  • JEONG JH, KIM SW, PARK TG: Anew antisense oligonucleotide delivery system based on self-assembled ODN-PEG hybrid conjugate micelles./ Control. Release (2003) 93(2):183–191.
  • •Research paper demonstrating that complex micelles, pegylated ODNs and PEI can effectively supress tumour growth.
  • JEONG JH, KIM SW, PARK TG: Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug. Chem. (2003) 14(2):473–479.
  • HANGELAND JJ, LEVIS JT, LEE YC et al.: Cell type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3. Bioconjug. Chem. (1995) 6(6):695–701.
  • DUFF RJ, DEAMOND SF, ROBY C et al.: Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates. Methods Enqmol. (2000) 313:297–321.
  • BIESSEN EA, VIETSCH H, RUMP ET et al.: Targeted delivery of antisense oligonucleotides to parenchymal liver cells in vivo. Methods Enqmol. (2000) 314:324–342.
  • COREY D: 48000-fold accelaration of hybridization by chemically modified oligonucleotides. J. Am. Chem. Soc. (1995) 117(30:9373–9374.
  • NEUMAN BW, STEIN DA, KROEKER AD et al: Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth. J. Wrol. (2004) 78(11):5891–5899.
  • MURATOVSKA A, ECCLES MR: Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. (2004) 558(1-3):63–68.
  • BERTRAND JR, POTTIER M, VEKRIS A et al.: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. (2002) 296(4):1000–1004.
  • JULIANO RL, ALAHARI S, Y00 H, et al.: Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. (1999) 16(4):494–502.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.